This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store?
by Zacks Equity Research
Edward Lifesciences Corp. (EW) is scheduled to report first-quarter 2017 earnings results after market close on Apr 25.
Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings?
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) is expected to report first-quarter 2017 results on Apr 27, before the opening bell.
ResMed (RMD) Q3 Earnings: Disappointment in the Cards?
by Zacks Equity Research
ResMed Inc. (RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.
IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store?
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is slated to report first-quarter 2017 results on Apr 28, before the opening bell.
Can Illumina (ILMN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Illumina Inc. (ILMN), a leading provider of tools and integrated systems for analysis of genetic variation and function, is scheduled to report first-quarter 2017 financial results on Apr 25, after the closing bell.
Integra LifeSciences (IART) Q1 Earnings: A Beat in Store?
by Zacks Equity Research
We expect Integra LifeSciences Holdings Corporation (IART) to beat expectations when it reports its first-quarter 2017 results, after market close on Apr 26.
GNC Holdings (GNC) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
GNC Holdings, Inc. (GNC) -- a specialty retailer of health and nutrition related products -- is scheduled to report first-quarter 2017 financial results on Apr 18, before the opening bell.
What's in Store for Walgreens Boots (WBA) in Q2 Earnings?
by Zacks Equity Research
Walgreens Boots Alliance, Inc (WBA) is slated to release second-quarter 2017 results, before the market opens on Apr 5.
Can Syros Pharmaceuticals (SYRS) Run Higher on Strong Earnings Estimate Revisions?
by Anupama Mukhopadhyay
Syros Pharmaceuticals (SYRS) seems to be a compelling pick on the back of its solid estimate revisions both in the current year and the current quarter.
Can The Uptrend Continue for Syros Pharmaceuticals (SYRS)?
by Zacks Equity Research
Investors certainly have to be happy with Syros Pharmaceuticals Inc (SYRS) and its short term performance
Syros Pharmaceuticals Stock: 3 Reasons Why SYRS Is a Top Choice for Momentum Investors
by Zacks Equity Research
Let's focus on Syros Pharmaceuticals, Inc. (SYRS) as this momentum stock is looking especially impressive right now.